The European LeukemiaNet AML Working Party consensus statement on allogenic HSCT for patients with AML in remission: an integrated-risk adapted approach
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.